Literature DB >> 16403060

Clinical predictors of noninducibility of sustained atrial fibrillation after pulmonary vein isolation.

Martin Rotter1, Pierre Jaïs, Stephane Garrigue, Prashanthan Sanders, Mélèze Hocini, Li-Fern Hsu, Yoshihide Takahashi, Thomas Rostock, Fréderic Sacher, Jacques Clementy, Michel Haïssaguerre.   

Abstract

BACKGROUND: Noninducibility of sustained atrial fibrillation (AF) after pulmonary vein isolation (PVI) has been shown to be associated with a better clinical outcome. We evaluated the role of clinical variables that could predict noninducibility of sustained AF after PVI. METHODS AND
RESULTS: Data were collected prospectively from 181 patients (153 male; age 54 +/- 9 years) referred for ablation of drug-refractory symptomatic paroxysmal AF (duration < or =7 days). Clinical variables were evaluated with regard to their ability of predicting noninducibility of sustained AF (< or =10 minutes) after PVI. Univariate analysis was performed on all collected variables followed by multivariate analysis for variables showing a P value <0.1. After PVI, sustained AF was noninducible in 97 (54%) patients. The following clinical variables showed a significant difference between the groups: body weight, longest AF episode, duration of AF history, presence or absence of structural heart disease, left ventricular (LV) hypertrophy, prior cardioversion, left atrial (LA) parasternal, and longitudinal diameters and LV diameters. On multivariate analysis, three independent predictors of noninducibility were identified: a shorter duration of AF episodes (AF <12 hours: RR 0.01 (0.002-0.06), P < 0.001; AF 12-48 hours: RR 0.07 (0.01-0.37), P = 0.001); LA longitudinal diameter <57 mm (RR 0.33 (0.13-0.82), P = 0.016); and absence of LV hypertrophy (RR 0.15 (0.04-0.63), P = 0.01).
CONCLUSIONS: Shorter AF episodes, smaller LA longitudinal diameter, and absence of LV hypertrophy are independent predictors of noninducibility of sustained AF after PVI.

Entities:  

Mesh:

Year:  2005        PMID: 16403060     DOI: 10.1111/j.1540-8167.2005.00225.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  5 in total

1.  Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin.

Authors:  Fang Liu; Mark D Levin; Nataliya B Petrenko; Min Min Lu; Tao Wang; Li Jun Yuan; Andrea L Stout; Jonathan A Epstein; Vickas V Patel
Journal:  J Mol Cell Cardiol       Date:  2008-09-16       Impact factor: 5.000

2.  Arrhythmia Termination Versus Elimination of Dormant Pulmonary Vein Conduction as a Procedural End Point of Catheter Ablation for Paroxysmal Atrial Fibrillation: A Prospective Randomized Trial.

Authors:  Cathrin Theis; Torsten Konrad; Hanke Mollnau; Sebastian Sonnenschein; Denise Kämpfner; Maik Potstawa; Blanca Quesada Ocete; Karsten Bock; Ewald Himmrich; Thomas Münzel; Thomas Rostock
Journal:  Circ Arrhythm Electrophysiol       Date:  2015-08-21

3.  Association between reactive hyperemia peripheral arterial tonometry index and atrial fibrillation recurrence after catheter ablation.

Authors:  Hideki Kobayashi; Ayako Okada; Hiroaki Tabata; Wataru Shoin; Takahiro Okano; Koji Yoshie; Yasutaka Oguchi; Ken Kato; Morio Shoda; Koichiro Kuwahara
Journal:  Int J Cardiol Heart Vasc       Date:  2019-06-20

4.  Clinical characteristics to guide the extent of ablation in paroxysmal AF patients: discovering an old science.

Authors:  Anthony G Brooks; Narayanan Namboodiri; Prashanthan Sanders
Journal:  Indian Pacing Electrophysiol J       Date:  2009-05-15

5.  Inducibility of atrial tachyarrhythmias after circumferential pulmonary vein isolation in patients with paroxysmal atrial fibrillation: clinical predictor and outcome during follow-up.

Authors:  Kazuhiro Satomi; Roland Tilz; Seiji Takatsuki; Julian Chun; Boris Schmidt; Dietmar Bänsch; Matthias Antz; Thomas Zerm; Andreas Metzner; Bülent Köktürk; Sabine Ernst; Heiner Greten; Karl-Heinz Kuck; Feifan Ouyang
Journal:  Europace       Date:  2008-05-19       Impact factor: 5.214

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.